Phillyrin

发表于由

上海金畔生物科技有限公司提供天然产物萜类及其苷类Terpenoids and Glycosides。

Phillyrin  纯度: 98.99%

Phillyrin 是从连翘中分离出来的，具有抗菌和消炎作用。Phillyrin 对大鼠 CYP1A2 和 CYP2D1 具有潜在的诱导作用，而不会影响 CYP2C11 和 CYP3A1/2 活性。Phillyrin 具有抗甲型流感病毒的活性。

Phillyrin

Phillyrin Chemical Structure

CAS No. : 487-41-2

规格 价格 是否有货 数量
10 mM * 1 mL in DMSO ￥588 In-stock
5 mg ￥500 In-stock
10 mg ￥800 In-stock
20 mg ￥1400 In-stock
50 mg   询价  
100 mg   询价  

* Please select Quantity before adding items.

Phillyrin 相关产品

•相关化合物库:

  • Natural Product Library Plus
  • Drug Repurposing Compound Library Plus
  • FDA-Approved Drug Library Plus
  • FDA-Approved Drug Library Mini
  • Bioactive Compound Library Plus
  • Anti-Infection Compound Library
  • Immunology/Inflammation Compound Library
  • Metabolism/Protease Compound Library
  • Natural Product Library
  • FDA-Approved Drug Library
  • Anti-Cancer Compound Library
  • Antiviral Compound Library
  • Anti-Aging Compound Library
  • Drug Repurposing Compound Library
  • Antioxidants Compound Library
  • Glycoside Compound Library
  • Oxygen Sensing Compound Library
  • Antibacterial Compound Library
  • Anti-COVID-19 Compound Library
  • NMPA-Approved Drug Library
  • Terpenoids Library
  • Traditional Chinese Medicine Monomer Library
  • FDA Approved & Pharmacopeial Drug Library

生物活性

Phillyrin is isolated from Forsythia suspensa Vahl (Oleaceae), has antibacterial and anti-inflammatory activities. Phillyrin has potential inductive effects on rat CYP1A2 and CYP2D1 activities, without affecting CYP2C11 and CYP3A1/2 activities[1]. Phillyrin has anti-influenza A virus activities[2].

IC50 & Target

CYP1A2; CYP2D1[1]
体外研究
(In Vitro)

Phillyrin (1–5 μM; pretreatment 1 hour; 24 hours) inhibits high glucose-induced FAS protein significantly in HepG2 cells[1].
Phillyrin (1–5 μM; pretreatment 1 hour; 24 hours) inhibits high glucose-induced FAS mRNA expression by suppressing SREBP-1c activation in human HepG2 hepatocytes[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

RT-PCR[1]

Cell Line: Human HepG2 hepatocyte cells
Concentration: 1 μM; 2.5 μM; 5 μM
Incubation Time: 24 hours
Result: Reduced FAS and SREBP-1c mRNA expression.

分子量

534.55

Formula

C27H34O11
CAS 号

487-41-2
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
溶解性数据
In Vitro: 

DMSO : 260 mg/mL (486.39 mM; Need ultrasonic)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 1.8707 mL 9.3537 mL 18.7073 mL
5 mM 0.3741 mL 1.8707 mL 3.7415 mL
10 mM 0.1871 mL 0.9354 mL 1.8707 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用； 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂： 10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 2.17 mg/mL (4.06 mM); Clear solution

    此方案可获得 ≥ 2.17 mg/mL (4.06 mM，饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例，取 100 μL 21.7 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液

  • 2.

    请依序添加每种溶剂： 10% DMSO    90% (20% SBE-β-CD in saline)

    Solubility: ≥ 2.17 mg/mL (4.06 mM); Clear solution

    此方案可获得 ≥ 2.17 mg/mL (4.06 mM，饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例，取 100 μL 21.7 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。

    将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
  • 3.

    请依序添加每种溶剂： 10% DMSO    90% corn oil

    Solubility: ≥ 2.17 mg/mL (4.06 mM); Clear solution

    此方案可获得 ≥ 2.17 mg/mL (4.06 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例，取 100 μL 21.7 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

*以上所有助溶剂都可在 Shanghai Jinpan Biotech Co Ltd 网站选购。
参考文献

  • [1]. Cheng Y, et al. Effects of phillyrin and forsythoside A on rat cytochrome P450 activities in vivo and in vitro. Xenobiotica. 2017 Apr;47(4):297-303.

    [2]. Qu XY, et al. Protective effects of phillyrin against influenza A virus in vivo. Arch Pharm Res. 2016 Jul;39(7):998-1005.

    [3]. Do MT, et al. Phillyrin attenuates high glucose-induced lipid accumulation in human HepG2 hepatocytes through the activation of LKB1/AMP-activated protein kinase-dependent signalling. Food Chem. 2013 Jan 15;136(2):415-25.